We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Concert Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 85 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 85 → 0 (-85)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $203M → $0 (-$203M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 85

Holders
–
Holders Change
-85
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
85
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
KCM
Kynam Capital Management
New Jersey
-$25.8M
2
BI
BVF Inc
California
-$21.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$11.2M
4
NCM
Nantahala Capital Management
Connecticut
-$10.1M
5
Millennium Management
Millennium Management
New York
-$8.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
51
683 Capital Management
New York
– -$222K -38,058 Closed
LSAG
52
Lake Street Advisors Group
New Hampshire
– -$207K -35,398 Closed
AA
53
ALPS Advisors
Colorado
– -$190K -32,516 Closed
Jane Street
54
Jane Street
New York
– -$172K -29,404 Closed
Marshall Wace
55
Marshall Wace
United Kingdom
– -$170K -29,030 Closed
Man Group
56
Man Group
United Kingdom
– -$156K -26,769 Closed
OQS
57
Occudo Quantitative Strategies
Florida
– -$143K -24,418 Closed
LIP
58
Lighthouse Investment Partners
Florida
– -$121K -20,746 Closed
SG Americas Securities
59
SG Americas Securities
New York
– -$119K -20,361 Closed
BC
60
Birchview Capital
Vermont
– -$117K -20,000 Closed
BFM
61
Boothbay Fund Management
New York
– -$108K -18,414 Closed
Bank of New York Mellon
62
Bank of New York Mellon
New York
– -$102K -17,528 Closed
Charles Schwab
63
Charles Schwab
California
– -$91.6K -15,686 Closed
HSBC Holdings
64
HSBC Holdings
United Kingdom
– -$88K -15,571 Closed
MFS
65
Mirabella Financial Services
United Kingdom
– -$90K -15,410 Closed
JF
66
Jump Financial
Illinois
– -$84.2K -14,418 Closed
CF
67
Cantor Fitzgerald
New York
– -$70K -12,000 Closed
FHA
68
Flagship Harbor Advisors
Massachusetts
– -$60.4K -10,350 Closed
RAM
69
Roanoke Asset Management
New Jersey
– -$58K -10,000 Closed
TRCT
70
Tower Research Capital (TRC)
New York
– -$43K -7,398 Closed
UBS Group
71
UBS Group
Switzerland
– -$42.6K -7,301 Closed
Simplex Trading
72
Simplex Trading
Illinois
– -$33K -5,789 Closed
Belvedere Trading
73
Belvedere Trading
Illinois
– -$29.4K -5,029 Closed
NA
74
NewEdge Advisors
Louisiana
– -$20.5K -4,015 Closed
KIA
75
Kraematon Investment Advisors
Massachusetts
– -$14.8K -2,535 Closed
1 2
3
4

CNCE Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2023, worth a combined $0 — down 100% from $203M a quarter earlier.

Sellers outnumbered buyers: 85 funds closed out of CNCE and 0 opened new positions — a net loss of 85 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Kynam Capital Management, exiting entirely with an estimated $25.8M sold.

  • 0 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $0 of Concert Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2023 and 85 closed out, a net change of -85 holders.
  • The largest Concert Pharmaceuticals, Inc. seller in Q1 2023 was Kynam Capital Management, an estimated $25.8M sold.

Based on aggregated 13F filings for Q1 2023.